CytomX Therapeutics Inc (CTMX) — Capital Reinvestment Ratio

Latest as of March 2023: 0.01x

CytomX Therapeutics Inc (CTMX) has a Capital Reinvestment Ratio of 0.01x as of March 2023, meaning it reinvests 0% of its operating cash flow ($9.35 Million) in capital expenditures ($48.00K). See how leveraged is CytomX Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$9.35 Million
USD

Capital Expenditures

$48.00K
USD

Data as of

Mar 2023
Most recent filing

CytomX Therapeutics Inc Capital Reinvestment Ratio (2014–2020)

This chart tracks CytomX Therapeutics Inc's Capital Reinvestment Ratio across 3 annual periods. Check CytomX Therapeutics Inc (CTMX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for CytomX Therapeutics Inc (2014–2020)

Year-by-year Capital Reinvestment Ratio for CytomX Therapeutics Inc from 2014 to 2020. For live market cap and broader valuation context, see CTMX stock market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.44x $5.26 Million $2.31 Million ▲ +4698.2%
2017 0.01x $170.37 Million $1.56 Million ▼ -82.5%
2014 0.05x $31.80 Million $1.66 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow